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SUMMARY. We compared the cost-effectiveness of various
noninvasive tests (NITs) in patients with chronic hepatitis
B and elevated transaminases and/or viral load who would
normally undergo liver biopsy to inform treatment deci-
sions. We searched various databases until April 2012. We
conducted a systematic review and meta-analysis to calcu-
late the diagnostic accuracy of various NITs using a bivari-
ate random-effects model. We constructed a probabilistic
decision analytical model to estimate health care costs and
outcomes quality-adjusted-life-years (QALYs) using data
from the meta-analysis, literature, and national UK data.
We compared the cost-effectiveness of four decision-making
strategies: testing with NITs and treating patients with
fibrosis stage ≥F2, testing with liver biopsy and treating
patients with ≥F2, treat none (watchful waiting) and treat
all irrespective of fibrosis. Treating all patients without prior
fibrosis assessment had an incremental cost-effectiveness
ratio (ICER) of £28 137 per additional QALY gained for
HBeAg-negative patients. For HBeAg-positive patients,
using Fibroscan was the most cost-effective option with an
ICER of £23 345. The base case results remained robust in
the majority of sensitivity analyses, but were sensitive to
changes in the ≥F2 prevalence and the benefit of treatment
in patients with F0–F1. For HBeAg-negative patients,
strategies excluding NITs were the most cost-effective:
treating all patients regardless of fibrosis level if the high
cost-effectiveness threshold of £30 000 is accepted; watch-
ful waiting if not. For HBeAg-positive patients, using
Fibroscan to identify and treat those with ≥F2 was the
most cost-effective option.
Keywords: cirrhosis, fibroscan, fibrosis, incremental cost-
effectiveness ratio, prognosis, quality-adjusted-life-years.
INTRODUCTION
It is estimated that 350–400 million people worldwide are
hepatitis B virus (HBV) carriers [1] and are therefore at
risk for progressive liver disease leading to cirrhosis and
hepatocellular cancer (HCC) with associated increased mor-
bidity and mortality. To prevent such progression, antiviral
treatment is administered to patients who fulfil certain cri-
teria, based on a combined assessment of viral load,
transaminase level and/or liver fibrosis. Indeed, EASL
guidelines state that patients should be considered for
antiviral treatment when they have HBV DNA levels
>2000 IU/mL, serum ALT levels above the upper limit of
normal and severity of liver disease as assessed by liver
biopsy (or noninvasive markers once validated in HBV-
infected patients) showing at least moderate necroinflam-
mation and/or fibrosis [1].
The current reference standard for assessing liver fibrosis
is the histological evaluation of liver biopsy with scoring
systems such as METAVIR or Ishak [2,3]. However, liver
biopsy is an invasive and costly procedure, inconvenient to
patients and associated with a small risk of significant
Abbreviations: CEAF, cost-effectiveness frontier; CHB, chronic hep-
atitis B; CI, confidence intervals; FN, false negative; FP, false posi-
tive; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; ICER,
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bleeding (1.1–1.6%) [4,5]. Alternatives to liver biopsy
include noninvasive fibrosis tests (NITs), which can be
broadly divided into three categories: simple/indirect serum
markers, direct or patented serum markers and imaging
modalities. Simple serum NITs, such as APRI and FIB4,
consist of readily available indirect markers of fibrosis such
as ALT, AST and platelet count, and are associated with
lower costs. Other serum tests such as Fibrotest are
patented and must be performed in laboratories that meet
certain quality standards, and are therefore more expensive
and less available. Transient elastography, which is per-
formed with Fibroscan, is the most widely used imaging
modality and measures liver stiffness based on ultrasound
principles using dedicated equipment. Simple NITS, such as
APRI and FIB-4 have two cut-offs for diagnosing specific
fibrosis stages, as the use of a single cut-off would result in
suboptimal sensitivity and specificity. These are a high cut-
off with high specificity or a low cut-off with high sensitiv-
ity. A combined cut-off uses the low cut-off to rule out the
presence of a particular stage of fibrosis, and the high cut-
off to confirm that the patient has a particular stage of
fibrosis [16]. However, a number of patients fall in the
indeterminate range of test results (i.e. their score is
between the low and the high cut-off) and need alternative
testing or future re-testing.
Noninvasive tests may offer cost-effective alternatives to
liver biopsy. However, currently there are no studies that
assess their cost-effectiveness in patients with chronic hep-
atitis B (CHB) within a health care setting. We assessed the
diagnostic accuracy and cost-effectiveness of NITs in
patients with CHB, who would normally undergo liver
biopsy to inform treatment decisions.
METHODS
Systematic review
We performed a systematic review and meta-analysis to
determine the diagnostic accuracy of NITs compared to
liver biopsy in adult patients with CHB. This study was
part of a larger project funded by the UK National Institute
of Health Research (NIHR) Health Technology Assessment
Programme [6] that determined the cost-effectiveness of
noninvasive tests in patients with CHB, hepatitis C [7],
alcoholic liver disease and nonalcoholic fatty liver disease.
Study selection and data extraction
We included full papers and abstracts which provided the
data necessary to determine the number of true positive
(TP), true negative (TN), false positive (FP) and false nega-
tive (FN) results of the NITs for ≥F2 using liver biopsy as
the reference standard, irrespective of language or publica-
tion status and whether the data were collected prospec-
tively or retrospectively. We excluded studies which
reported on fewer than 10 patients and when the maxi-
mum interval between liver biopsy and the NITs was
>6 months.
The search strategy, data extraction and analysis were
performed as previously described [7] and are detailed in
the Appendix S1.
The quality of the included studies was assessed using
the Quality Assessment of Diagnostic Accuracy Studies
(QUADAS)-2 assessment tool [8]. The criteria used for
QUADAS-2 assessment are shown in the Appendix S1.
Economic model
Approach to analysis
The systematic review identified a total of 25 NITs; how-
ever the quantity and quality of the evidence varied
between the NITs (Table 1). The base case cost-effective-
ness analysis compared those NITs for which data on sen-
sitivity and specificity were considered robust, defined as
whether the bivariate model used in the meta-analysis con-
verged (n = 5): APRI (high cut-off and low cut-off); Fibros-
can; Fibrotest; and FIB4 (low cut-off). We compared the
cost-effectiveness of NITs based on four different antiviral
treatment scenarios: (i) treat all patients without prior
fibrosis evaluation, (ii) treat no patients and no fibrosis
evaluation to inform this decision (watchful waiting), (iii)
biopsy all patients and treat those with a METAVIR fibrosis
stage ≥F2, (iv) test with NIT and treat patients with a
METAVIR fibrosis stage ≥F2.
Model structure
The analyses were based on a decision tree framework,
combined with a Markov model to estimate the long-term
costs and outcomes associated with each potential test
diagnosis: TP, FP, FN or TN and the ‘treat all’ and ‘treat
no one’ testing strategies.
The Markov model estimated the health outcomes and
costs for a hypothetical cohort of 1000 CHB patients with
suspected fibrosis, who would usually present for liver
biopsy. Separate Markov models were constructed for the
HBeAg- positive and HBeAg-negative patient cohorts to
reflect differences in disease progression and patient char-
acteristics. The structural assumptions underlying the state
transition models applied to both groups of patients. Fig-
ure 1 provides a schematic illustration of the pathway.
The cohort of 1000 CHB patients started the model in
either the mild, moderate or cirrhotic health states (≤F4),
depending on the outcome being modelled (TN, TP, FP,
FN, treat all and treat no-one). The distribution of the pop-
ulation among the different health states was based on the
prevalence data from the systematic review. The Markov
models were evaluated over a lifetime period with a cycle
length of 1 year. Health outcomes were expressed as qual-
ity-adjusted-life-years (QALYs), which combine data on life
expectancy with data reflecting quality of life. All unit costs
© 2015 John Wiley & Sons Ltd
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reported in the analysis for health states and liver biopsy,
are priced for the year 2012 and were considered from the
perspective of the UK National Health System (NHS). Costs
and QALYs were discounted using a rate of 3.5% [9]. Cost-
effectiveness was assessed according to thresholds used by
the UK National Institute for Health and Care Excellence,
which include a threshold of £20 000, increasing up to
around £30 000 when specific additional considerations
are important [9].
The decision tree was populated with results from the
Markov model, summary sensitivity and specificity esti-
mates and average disease prevalence estimate (METAVIR
≥F2 extracted from the meta-analysis), to estimate the
cost-effectiveness of all comparators.
Input parameters
Current recommended treatment options for chronic CHB
include indefinite treatment with nucleoside or nucleotide
analogues or pegylated interferon alpha for a period of
12 months [1]. Treatment with antiviral agents, entecavir
or tenofovir (50–50 split) was initiated in the model for a
patient with positive (METAVIR ≥F2) diagnosis. Only
patients in the moderate fibrosis, compensated cirrhosis or
decompensated cirrhosis health states received treatment
with antiviral agents. Patients in the HCC, liver transplant
and post-liver transplant health states received usual stan-
dard of care. Treatment effectiveness was sourced from a
published meta-analysis by Woo et al. [10]; treatment effi-
cacy of the drugs (represented by relative risks in the
model) are listed in Table 2.
Treatment with peginterferon alfa-2a was given for a
1 year period to 10% of those who tested negative to
reflect a proportion of patients who may not have fibrosis
but would receive treatment for necroinflammation [1].
We assumed that 30% of these TN patients who received
treatment for 1 year would have a successful response to
treatment and would no longer progress to more advanced
disease stages. The remaining 90% who initially tested
negative and those who had an unsuccessful response to
peginterferon alfa-2a treatment underwent a ‘watchful
waiting’ process which incorporated a re-test with an NIT
every 2 years. If patients in the model had progressed to a
≥F2 health state at the time of re-test, they received imme-
diate treatment with antivirals (entecavir and tenofovir).
We tested this assumption in a sensitivity analysis.
The rate of disease progression in the Markov model was
sourced from a published cost-effectiveness study by Dakin
et al. [11]; however, this study did not report separate
transition probability data for the precirrhotic health states
(mild and moderate fibrosis). In the absence of transition
probability data for the mild and moderate health states,
we used data from a study of patients with mild chronic
hepatitis C [12]. We assumed that the progression of early
fibrosis would not differ significantly in patients with HCV
and HBV.T
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We sourced health state costs and health-related utility
estimates, based on patients’ self-reported health status
using the EQ-5D questionnaire [13], for the earlier dis-
ease stages (≤F4) from the study of patients with mild
hepatitis C [12]. We assumed that the resource use
identified and collected for this study (inpatient, outpa-
tient and procedures, excluding medication costs)
would be similar for patients with HCV and HBV; addi-
tionally this was the only study which estimated
separate utilities for the mild and moderate health
states (using EQ-5D). We sourced costs and utilities
for later disease stages (>F4) from a cost-effectiveness
study of liver transplantation [14], for which resource-
use and EQ-5D data were available for a subgroup of
patients with CHB. As we used two different sources of
data, we conducted a sensitivity analysis using different
utility values and health state costs for the later disease
stages.
Cohort characteristics, mortality data, and treatment
costs were sourced from published literature and routine
national UK sources. Input parameters and sources are
listed in Table 2. Costs for the NITs and liver biopsy are
listed in the Appendix S1.
Analysis and uncertainty
We conducted an incremental analysis to identify the cost-
effective testing strategy. We ruled out tests strategies
which were more costly and less effective ‘dominated’. We
then estimated Incremental Cost-Effectiveness Ratios
(ICER), for the remaining NITs, where they were compared
to the next best alternative, calculated using the formula:
ICER ¼ ½ðC1  C0Þ=ðE1  E0Þ;
where C1 = lifetime cost of strategy 1; C0 = lifetime cost of
(the next best) strategy; E1 = QALYs from strategy 1 and
E0 = QALYs from (the next best) strategy.
Test strategies with an ICER greater than that of a more
effective intervention (extendedly dominated) were also
ruled out and the remaining tests were then compared to
identify the NIT with the highest ICER given a £20 000
per QALY threshold.
A probabilistic sensitivity analysis was run to estimate
uncertainty in the mean results. We constructed the
cost-effectiveness frontier (CEAF), which plots the
uncertainty associated with the optimal option (test with
highest expected net benefit), for different values of the
Fig. 1 Illustration of the Markov Model used for economic analysis. The disease stages reflect the METAVIR staging score
for liver fibrosis and cirrhosis. The cohort represents people suspected of liver fibrosis who can enter the models in one of
three disease stages; mild fibrosis (METAVIR stages F0–F1), moderate fibrosis (METAVIR stages F2–3) and compensated
cirrhosis (METAVIR stage F4) with the proportions determined by the prevalence estimated from the results of the
systematic review. Within the model, people can remain within any disease stage for longer than one cycle (length of cycle
is set as 1 year) except for the liver transplant disease stage where patients can only progress to either a post-liver
transplant stage or death.
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Table 2 Input parameters for model
Model inputs Parameter value Distribution Source
Cohort characteristics
HBeAg-positive
Starting age 31 years
Gender % male 70% Shepherd et al. [25]
HBeAg-negative
Starting age 40 years
Gender % male 90%
Natural history data (Transition probabilities)
Mild-moderate fibrosis 0.025 Dirichlet
Moderate fibrosis-compensated Cirrhosis (HBeAg-positive) 0.037 Wright et al. [12]
Moderate Fibrosis-compensated cirrhosis (HBeAg-negative) 0.09
Compensated cirrhosis-decompensated cirrhosis 0.05
Moderate Fibrosis-Hepatocellular Cancer (HCC) 0.048 Dakin et al. [11]
Cirrhosis to HCC 0.024
Decompensated cirrhosis/HCC- liver transplant 0.016
Decompensated cirrhosis-death 0.30
Liver transplant-death 0.21
Post Liver transplant-death 0.057
Excess mortality
Moderate fibrosis 0.035
Compensated cirrhosis 0.051
HCC 0.56
Treatment dosage
Peginterferon alfa-2a 180 mg (weekly)
Entecavir 500 mg (daily) British National
Formulary 64
Tenofovir 245 mg (daily)
Treatment efficacy (Relative risks)
Mean CI upper CI lower Distribution Source
HBeAg-positive
Entecavir 0.56 0.12 0.94 Gamma
Tenofovir 0.53 0.06 0.95 Gamma Woo et al. [10]
Peginterferon alfa-2a 0.52 0.06 0.95 Lognormal
HBeAg-negative
Entecavir 0.64 0.01 1.00 Gamma
Tenofovir 0.65 0.01 1.00 Gamma Woo et al. [10]
Peginterferon alfa-2a 0.52 0.06 0.95 Log Normal
Health state costs
Mean SE Distribution Source
Mild fibrosis 185 36.39 Gamma Wright et al. [12]
Moderate fibrosis 986 101.69
Compensated cirrhosis 1521 309.05
Decompensated cirrhosis 36 194 9967.19 Gamma Longworth et al. [14]
Hepatocellular cancer 36 194 9967.19
Liver transplant 64 122 5584.70
(continued)
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cost-effectiveness threshold (threshold value range varied
from £0 to £60 000) [15].
Secondary analyses
We conducted a secondary analysis where we evaluated
the sequential use of NITs (see appendix for sequential test-
ing strategies).
We also carried out an analysis where we evaluated all
identified NITs (n = 25), regardless of their robustness (ro-
bustness was defined as to whether the bivariate model
converged for meta-analysis).
Sensitivity analysis
A number of one way sensitivity analyses were undertaken
to vary some of the input parameters in the model, includ-
ing changes to utility values, health state costs, average
disease prevalence, assumption of treatment benefit for FP
patients (mild health state F0-1) and the re-test assump-
tion of perfect sensitivity and specificity.
RESULTS
Systematic review
The selection flow chart for studies is shown in the Appen-
dix S1. Data on patients with CHB were extracted from 52
studies that evaluated 25 different NITs. NIT cut-offs for
the diagnosis of specific histological stages were not always
predetermined, and consequently varied. We opted not to
perform a separate meta-analysis for each stage-specific
cut-off of a NIT, but to group together cut-offs if the range
was reasonable. Therefore, when a range of cut-offs is
mentioned in the results tables, the reported sensitivities
and specificities are probably overestimated.
The summary sensitivities and specificities for each test
are presented in Table 1. The average prevalence of META-
VIR score ≥F2 in the included studies was 54%. All but
one study had a high risk of bias as assessed by the QUA-
DAS-2 tool (Appendix S1) therefore our results should be
interpreted with caution. Strikingly, the cut-offs of the NITs
were predefined in 11/52 (21%) studies, while liver biopsy
was of adequate quality (≥6 portal tracts and ≥15 mm) in
12/52 (23%) studies.
Economic modelling
HBeAg-negative chronic hepatitis B
The most effective strategy to employ is ‘treat all without
prior diagnostic testing’, which had an ICER of £28 137.
This would only be considered cost-effective if the £30 000
upper bound of the UK cost-effectiveness threshold range is
considered acceptable; if not, a strategy of ‘treat no one’
would be the most cost-effective. All other testing strategies
are dominated by the ‘treat all’ strategy, as they are more
costly and less effective. Table 3 displays results of the base
case analysis.
Table 2 (continued)
Health state costs
Mean SE Distribution Source
Post-liver transplant 16 321 7932.51
Utilities
Mild fibrosis 0.77 0.035 Wright et al. [12]
Moderate fibrosis 0.66 0.0.18 Gamma
Compensated cirrhosis 0.55 0.032
Decompensated cirrhosis 0.57 0.076 Gamma Longworth et al. [14]
Hepatocellular cancer 0.57 0.076
Liver transplant 0.55 0.016
Post Liver transplant 0.78 0.064
Mild Fibrosis (during treatment) 0.65 0.035 Gamma Wright et al. [12]
Moderate fibrosis (during treatment) 0.55 0.018
Compensated cirrhosis (during treatment) 0.45 0.040
Disutility following liver biopsy 0.2 Assumed
Treatment costs Annual Cost (UK £2012)
Peginterferon alfa-2a 6469
Entecavir 4420 British National Formulary 64
Tenofovir 2926
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The CEAF (Appendix S2) for the HBeAg-negative model
shows that the probability of ‘treat all’ being on average
the most cost-effective testing option given a cost-effective-
ness threshold value of £30 000, is 39%.
HBeAg-positive chronic hepatitis B
For HBeAg-positive patients at a cost-effectiveness thresh-
old of £30 000: the cost effective option to use when all
tests were compared was Fibroscan, with an ICER of
£23 345 (Table 4). However, the CEAF (Figure Appendix)
for the HBeAg-positive model shows that the probability of
Fibroscan being on average the most cost-effective testing
option given a cost-effectiveness threshold value of
£30 000 is low at 21%.
A testing strategy ‘treat all’ without prior diagnostic test-
ing provided a higher health gain (QALY) than Fibroscan,
however, this option had an ICER of £39 747 which
would not be acceptable given a £20 000–30 000 cost-ef-
fectiveness threshold.
Secondary analyses
A secondary analysis where we evaluated the use of more
than one NIT found that ‘treat all’ without prior diagnostic
testing remained the most cost-effective option for the
HBeAg-negative population with an ICER of £28 138,
whereas for the HBeAg-positive population, using APRI
(low cut-off) followed by Fibroscan using the second
sequential testing strategy (appendix) was the most cost-ef-
fective testing strategy with an ICER of £23 901 (see
Appendix S1).
An analysis evaluating all of the NITs identified during
the systematic review (irrespective of robustness) found
similar results for the HBeAg-negative population as the
base case analysis (Treat all with an ICER of £28 137).
However, for the HBeAg-positive population, Magnetic Res-
onance Elastography (MRE) was the most cost-effective
option with an ICER of £23 468. This analysis found that
several NITs had similar outcomes (cost and QALYs) (See
Appendix S1 for incremental analysis tables).
Sensitivity analysis results
HBeAg-negative
The base results remained robust to the majority of sensi-
tivity analyses; those they were sensitive to are detailed
below.
Using the starting age and gender split used in the
HBeAg-positive model changed the results for the HBeAg-
negative population so that Fibroscan became the most
cost-effective testing option with an ICER of £25 575.
Amending the ≥F2 prevalence used in the model (54%)
also changed the base results; when using a prevalence of
43% (lower quartile), the no testing and no treatment
option was the most cost-effective testing strategy (treat all
testing strategy had an ICER of £30 413). When the
Table 3 HBeAg –negative base case analysis
Testing option Cost £ QALYs Incremental cost £ Incremental QALY ICER £
Treat no one (no diagnostic test) 35 579 8.83 – – –
Liver biopsy 70 274 9.64 – – Dominated
APRI (high cut off) 69 429 9.71 – – Extendedly Dominated
Fibroscan 72 986 9.93 – – Extendedly Dominated
Fibrotest 73 857 9.94 – – Extendedly Dominated
FIB 4 (low cut off) 75 702 10.01 – – Extendedly Dominated
APRI (low cut off) 77 981 10.13 – – Extendedly Dominated
Treat all (no diagnostic test) 96 525 10.92 58 947 2.09 28 137
Table 4 HBeAg –positive base case analysis
Testing option Cost £ QALYs Incremental cost £ Incremental QALY ICER £
Treat no one (no diagnostic test) 37 831 9.64 – – –
Liver biopsy 75 957 11.41 – – Dominated
APRI (high cut off) 75 210 11.45 37 380 1.81 20 673
Fibroscan 79 000 11.61 3 790 0.16 23 345
Fibrotest 79 462 11.62 – – Extendedly Dominated
FIB 4 (low cut off) 81 382 11.67 – – Extendedly Dominated
APRI (low cut off) 83 788 11.75 – – Extendedly Dominated
Treat all (no diagnostic test) 101 484 12.18 22 484 0.57 39 474
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maximum prevalence of 92% was used, Fibroscan was the
most cost-effective test with an ICER of £21 853.
We also tested the assumption that not all patients were
diagnosed correctly at re-test (watchful waiting strategy for
patients who initially test negative) by using the sensitivity
and specificity estimates of three commonly used tests
[APRI (low cut-off), Fibrotest, and Fibroscan]. With this
analysis, Fibroscan became the most cost-effective test
when the sensitivity and specificity of Fibrotest or Fibros-
can were used (ICERs of £27 584 and £27 088 respec-
tively). There was no change to the base case results when
the sensitivity and specificity for APRI (low cut-off) was
used for the re-test.
In the base case all patients who tested positive (≥F2)
received treatment with antiviral agents. When we
assumed that patients in a mild health state (F0-1), who
were incorrectly diagnosed as having more advanced fibro-
sis (FP patients) would receive no benefit from treatment,
the results changed so that ‘treat no one’ became the most
cost-effective option (the ICER for treat all increased to
£35 081).
HBeAg-positive
The results were robust to the majority of sensitivity analy-
ses, apart from the analyses detailed below.
We carried out four analyses where we amended the
prevalence of ≥F2 used in the model. Amending the preva-
lence from 54% to 43% (lower quartile) changed the most
cost-effective test to APRI (high cut-off) with an ICER of
£19 989. When changing the prevalence to 65% (third
quartile), the most cost-effective testing option became
‘treat all’ irrespective of fibrosis stage with an ICER of
£24 615. When using the maximum prevalence of 92%,
APRI (high cut-off) became the most cost-effective test with
an ICER of £18 186. Using the minimum ≥F2 prevalence
(27%) also changed the most cost-effective test to APRI
(high cut-off) with an ICER of £19 464.
When we assumed that patients in a mild health state,
who were incorrectly diagnosed as having advanced fibro-
sis (FP patients), would receive no benefit from treatment,
the most cost effective test was APRI (high cut-off) with an
ICER of £21 122.
The results changed when we tested the assumption that
all persons were diagnosed correctly when a re-test was
performed (watchful waiting); APRI (low cut-off) became
the most cost-effective test when the sensitivity and speci-
ficity of APRI (low cut-off) or Fibrotest were used (ICERs of
£24 651 and 29 644 respectively). There was no change
to the base case results when the sensitivity and specificity
for Fibroscan was used for the re-test.
DISCUSSION
We compared five NITs with each other, liver biopsy and
a ‘treat all’ and ‘treat no one’ approach for informing
treatment decisions in chronic HBV patients. The overall
results differed for the HBeAg-positive and HBeAg-negative
patients.
In the HBeAg-negative population, treating all patients
based on viral load and ALT irrespective of the degree of
fibrosis offered the largest QALY gain with an ICER of
£28 317. There was some uncertainty in these results and
the ‘treat all strategy’ had a 39% probability of having the
highest net benefit, given a £30 000 cost-effectiveness
threshold. In the HBeAg-positive population the most cost-
effective testing option was Fibroscan, however this NIT
had a low (21%) probability of being the optimal testing
option given a £30 000 cost-effectiveness threshold.
Similar findings for treatment in patients with CHB have
been reported in assessments conducted to inform national
guidelines. For example, in the UK, entecavir for the treat-
ment of HBeAg-negative patients (assuming lifetime treat-
ment duration) had an ICER of £27 124/QALY gained
[17], similar to our base case analysis result. The fact that
antiviral treatment for CHB in the UK is cost-effective at a
£30 000 but not at a £20 000 cost-effectiveness threshold
reflects the high unit cost and lifetime duration of treat-
ment [17,18]. Currently, a third of UK patients with HBV
followed in liver centres are on antiviral treatment, how-
ever, only 18% of those treated are on recommended first-
line treatment [19].
The difference between the HBeAg-positive and negative
results can be attributed to differences in baseline charac-
teristics such as an older starting age within the model,
higher male population, higher risk of developing cirrhosis,
and the effectiveness of treatment in the HBeAg-negative
group.
Our data therefore suggest that liver biopsy is not cost-
effective for informing treatment decisions in patients with
CHB in the UK and most probably in most developed coun-
tries, with the caveat regarding local costs, preferences and
decision rules. A pragmatic cost-effective approach there-
fore would be to treat HBeAg() patients based on high
viral load and deranged ALT, irrespective of their fibrosis
level. For HBeAg(+) patients, the most cost-effective strat-
egy is to perform a Fibroscan to inform treatment decisions
in patients with high viral load and deranged ALT. This is
a deviation from the current EASL guidelines, where liver
biopsy is the preferred strategy irrespective of HBeAg sta-
tus. It also simplifies treatment decisions in HBeAg()
patients, who could be potentially seen in nurse-led outpa-
tient clinics.
Our meta-analysis of NITs has been the most detailed
and extensive to date, including all described serum tests
and imaging modalities with no language restrictions
and using state-of-the-art statistical and reporting meth-
ods. A striking finding of our meta-analysis was that the
vast majority of studies had high risk of bias and failed
in important methodological aspects, such as the absence
of predetermined test cut-offs and suboptimal quality of
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liver biopsy as the reference standard. Moreover, there
was a paucity of sufficiently evaluated and validated
NITs in patients with CHB. Indeed, there were adequate
data for a reliable meta-analysis in only four NITs,
namely APRI, FIB4, Fibroscan and Fibrotest. A recent
updated meta-analysis on APRI and FIB-4 showed simi-
lar diagnostic accuracy with the data presented in this
paper [20]. The increasingly used Fibroscan does not
have validated cut-offs for specific fibrosis stages. Pub-
lished cut-offs are based on post hoc analyses and have
not been prospectively validated in independent cohorts,
therefore the reported diagnostic accuracy is most likely
overestimated [21]. All tests performed significantly better
in diagnosing cirrhosis than lesser fibrosis stages. There-
fore, NITs in CHB need better quality studies and further
validation, particularly for the diagnosis of moderate
fibrosis.
Our economic modelling was performed from the per-
spective of an economy of a developed country and there-
fore its findings cannot be extrapolated to the developing
world. This would require a separate analysis with different
utilities and costs. A cost-effectiveness analysis of antiviral
treatment in middle-income countries has shown that this
is cost-effective, however the use of NITs was not factored
in the analysis [22]. However, the greatest burden of HBV
infection is encountered in low-income countries in Asia
and the sub-Saharan Africa. The World Health Organiza-
tion has recently launched guidelines for treatment of peo-
ple with CHB in such countries [23]. Treatment is
recommended in patients with deranged ALT and viral
load >2000 IU/ml or those with evidence of cirrhosis,
based on clinical finding or an APRI score of >2. The
choice of APRI was based on widespread availability rather
than cost-effectiveness analysis. Clearly, such countries
would require subsidised costs of antiviral treatment, simi-
lar to the paradigm of HIV infection, for these guidelines to
become applicable.
There are limitations to this analysis. Firstly, treatment
decisions are far more complex than fibrosis evaluation in
CHB, and depend on a global assessment that takes into
account HBeAg status, viral load, transaminases, fibrosis
and necroinflammation but also family history of HCC and
family planning in females. Indeed, in some patients the
decision to treat is straightforward without the need of a
liver biopsy, and in others even a ≥F2 would not necessar-
ily prompt treatment initiation. Therefore, this analysis is
relevant only for patients who would require a liver biopsy
to decide on treatment initiation, and not in unselected
patients with CHB.
Secondly, the assumption that the re-test carried out
during the watchful waiting process correctly identified all
patients who had progressed is a potential limitation; a
sensitivity analysis incorporating the sensitivity and speci-
ficity estimates of three NITs found that the base case
results did change for both populations, implying that this
assumption may underestimate the ICER of treating all
patients.
Thirdly, we did not include a health state specifically
describing seroconversion in the model structure. This was
for simplicity purposes as our outcome was treatment initi-
ation rather than treatment effectiveness. Although some
studies have shown that fibrosis and even cirrhosis can
regress with antiviral therapy [24], this is not factored into
the model. This may underestimate the cost-effectiveness of
treatment.
In conclusion, to our knowledge, this analysis is the first
to compare the cost-effectiveness of a number of different
NITs for use in patients with CHB. The current reference
standard, liver biopsy was more costly and less effective
than other tests in both the base case and sensitivity anal-
yses. We identified that treating all patients (if eligible for
treatment based on ALT and/or viral load) regardless of
fibrosis level is the most cost-effective strategy for HBeAg-
negative patients, whereas an NIT, Fibroscan is the most
cost-effective diagnostic strategy for HBeAg-positive
patients, although there is significant uncertainty around
this result. These findings were robust to several sensitivity
analyses.
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